araag2/HINT huggingface dataset:
Clinical trial NCT03029832 (phase 2, status: terminated)
Conditions: urothelial carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: moxr0916, atezolizumab
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1
Reason stopped: 
    the study was prematurely terminated due to slow patient accrual and discontinuation of
    clinical development of moxr0916 due to sponsor's strategic priorities.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age >= 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of <= 2

          -  Life expectancy >= 12 weeks

          -  Histologically or cytologically confirmed locally advanced or metastatic urothelial
             carcinoma (UC)

          -  Availability of a representative formalin-fixed paraffin-embedded tumor specimen

          -  No prior systemic therapy for inoperable locally advanced or metastatic UC

          -  Ineligible for cisplatin-based chemotherapy as defined by any one of the following
             criteria: Impaired renal function (glomerular filtration rate [GFR] > 30 but < 60
             milliliter/minute [mL/min]); National Cancer Institute Common Terminology Criteria for
             Adverse Events (NCI CTCAE) version (v) 4.0 Grade >= 2 audiometric hearing loss (of 25
             Decibel at two contiguous frequencies or more severe); NCI CTCAE v 4.0 Grade >= 2
             peripheral neuropathy; ECOG Performance Status of 2

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1

          -  Adequate hematologic and end-organ function

        Exclusion Criteria:

          -  Significant cardiovascular disease

          -  Known clinically significant liver disease

          -  Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3
             weeks prior to initiation of study treatment

          -  Prior treatment with CD137 or OX40 agonists, anti-cytotoxic T-lymphocyte-associated
             protein (CTLA4), anti-programmed death-1 (PD-1), anti- programmed death-ligand 1
             (PD-L1), anti-CD-27, anti- glucocorticoid-induced tumor necrosis factor receptor
             (GITR) therapeutic antibody or pathway-targeting agents

          -  Untreated central nervous system (CNS) metastases or active (progressing or requiring
             corticosteroids for symptomatic control) CNS metastases

          -  Any history of leptomeningeal disease

          -  Malignancies other than UC within 5 years prior to Cycle 1, Day 1

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or
             evidence of active pneumonitis on screening chest computed tomography scan

          -  Active hepatitis B and C virus infection

          -  Positive HIV test at screening

          -  Active tuberculosis

          -  Prior allogeneic stem cell or solid organ transplantation
Clinical trial NCT03033069 (phase 2, status: completed)
Conditions: stress disorders, post-traumatic
ICD codes: F43.10, F43.11, F43.12
Drugs: brexpiprazole (opc-34712), sertraline
SMILES: O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1, CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Male and Female subjects between the years of 18-65 with a diagnosis of PTSD
             (diagnosis can be made at screening)

        Exclusion Criteria:

          -  Index trauma event >15 years before screening

          -  Index trauma event at age <16

          -  Any traumatic event within 3 months of screening
Clinical trial NCT03034135 (phase 2, status: completed)
Conditions: recurrent glioblastoma
ICD codes: G47.13, J01.41, K11.22, K12.0, N96, F33.8, G03.2
Drugs: disulfiram/copper, temozolomide (tmz)
SMILES: CCN(CC)C(=S)SSC(=S)N(CC)CC, CN1N=NC2=C(N=CN2C1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed GBM (WHO grade IV).

          -  The subject must have completed RT with concurrent TMZ at least 12 weeks prior to the
             planned start of treatment on this study UNLESS there is pathological verification of
             recurrent tumor and at least 4 weeks have elapsed since the end of RT with concurrent
             TMZ.

          -  Experienced first unequivocal progression of tumor by magnetic resonance imaging (MRI)
             [as assessed via Radiologic Assessment in Neuro-Oncology (RANO) criteria within 3
             months from the last dose of TMZ.

          -  Karnofsky performance status (KPS) of at least 60%.

          -  Willing to remain abstinent from consuming alcohol.

          -  Recovered from the toxic effects of prior therapy to < grade 2 toxicity per NCI CTCAE
             prior to study registration (except lymphopenia).

          -  Meets laboratory criteria for the following parameters: ANC, platelets, hemoglobin,
             total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine
             aminotransferase, BUN and creatinine.

          -  11. Females of childbearing potential must be willing to use an acceptable method of
             birth control (i.e., intra-uterine device, diaphragm with spermicide, condom with
             spermicide, or abstinence) for the duration of the study.

        Exclusion Criteria:

          -  Radiographic evidence of leptomeningeal dissemination, gliomatosis cerebri,
             infratentorial tumor, or disease at sites remote from the supratentorial brain.

          -  Enrolled in another clinical trial testing a novel therapy or drug within the past 4
             weeks.

          -  Received more than one course of radiation therapy or more than a total dose of 75 Gy.

          -  History of allergic reaction/hypersensitivity to temozolomide, dacarbazine, DSF or Cu.

          -  Treatment with the following medications are contraindicated with DSF: metronidazole,
             isoniazid, dronabinol, carbocisteine, lopinavir, paraldehyde, ritonavir, sertraline,
             tindazole, tizanidine, atazanavir.

          -  Fever within 3 days prior to study enrollment.

          -  Active or severe hepatic or renal disease.

          -  Grade 2 or higher peripheral neuropathy or ataxia per NCI CTCAE

          -  History of idiopathic seizure disorder schizophrenia, or psychosis unrelated to
             glioblastoma, corticosteroid, or anti-epileptic medications.

          -  History of Wilson's disease.

          -  History of hemochromatosis.

          -  Pregnant or breastfeeding.
Clinical trial NCT03034772 (phase 2/phase 3, status: completed)
Conditions: neovascular age-related macular degeneration, wet macular degeneration
ICD codes: H35.3211, H35.3212, H35.3221, H35.3222, H35.3231, H35.3232, H35.3291, G23.2, G31.85, I51.5, K04.2, H18.40, H18.49, H35.30
Drugs: dorzolamide-timolol
SMILES: CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Active choroidal neovascularization (CNV) due to AMD.

          2. Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months
             and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during
             this period.

          3. Baseline CST ≥ 270 µm on SD-OCT automated retinal thickness map.

          4. Injection of the same anti-VEGF agent at each of the two visits immediately preceding
             study enrollment.

          5. Time interval of 5 weeks (± 1 week) between visits for at least two visits immediately
             preceding study enrollment.

          6. Subjects of either gender aged ≥ 45 years.

          7. Provide written informed consent

          8. Ability to comply with study and follow-up procedures and return for study visits.

        Exclusion Criteria:

          1. History of uveitis.

          2. Presence of intraocular inflammation, significant epiretinal membrane (causing
             distortion of macular anatomy per investigator discretion), significant vitreomacular
             traction (per investigator discretion), macular hole, or vitreous hemorrhage.

          3. Any ophthalmic surgery within previous 6 months, including cataract extraction.

          4. Any history of vitrectomy or glaucoma surgery (e.g., trabeculectomy, tube shunt).

          5. Current prescription eye drop usage (e.g., glaucoma drops, corticosteroid drops,
             etc.).

          6. Any contraindication for topical use of a beta-blocker (e.g., bradycardia,
             decompensated heart failure, chronic obstructive pulmonary disease, reactive airway
             disease, asthma, etc.).

          7. Any history of sulfonamide allergy.
Clinical trial NCT03036839 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Chronic HCV infected genotype 1, 2 (Taiwan only), 4, 5, or 6 male and nonpregnant/
             nonlactating females aged 18 years or older who are on dialysis for ESRD, including
             adults with HIV coinfection if they are suppressed on a stable, protocol-approved
             antiretroviral (ARV) regimens for ≥8 weeks prior to screening.

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT03036852 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: sof/vel
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Chronic HCV infected, male and non-pregnant/non-lactating females aged 18 years or
             older who are on dialysis for ESRD, including adults with HIV co-infection if they are
             suppressed on a stable, protocol-approved antiretroviral (ARV) regimen for ≥8 weeks
             prior to screening.

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Clinical trial NCT03042780 (phase 2, status: terminated)
Conditions: gastro-enteropancreatic neuroendocrine tumor, pancreatic cancer, neuroendocrine carcinomas of pancreas, islet cell carcinoma
ICD codes: C7A.1, C7A.8, C7B.8, D3A.8, C25.3, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: folfirinox, granulocyte colony-stimulating factor (g-csf)
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed neuroendocrine carcinoma of the
             gastrointestinal (GI) tract. Potential participants with unknown origin for the
             neuroendocrine carcinoma in which a gastroenteropancreatic origin is suspected (per
             pathologist or investigator discretion) will be eligible for the study.

          -  Tumors must have a Ki-67 index greater than 20% and/or >20 mitotic figures/10
             high-power fields.

          -  Must have metastatic disease.

          -  Must measurable disease, as defined by Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1.

          -  Any line of treatment (first line versus beyond first line).

          -  Age >18 years.

          -  Life expectancy of greater than 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

          -  Must have adequate organ and marrow function.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Have had chemotherapy or radiotherapy within 3 weeks prior to entering the study.

          -  Receiving any other investigational agents.

          -  Untreated brain or meningeal metastases.

          -  Prior treatment with 5-fluorouracil (5-FU), irinotecan or oxaliplatin.

          -  Pre-treatment peripheral neuropathy greater than grade 1 per the CTCAE, version 4.0.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  A secondary primary cancer (excluding baso/squamous cell carcinoma of skin) within 1
             year.

          -  Active viral hepatitis or autoimmune hepatitis. The work-up to confirm active
             hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on
             investigator discretion.

          -  Potential participants with childbearing potential who are not willing to use adequate
             contraception precautions during the study and for 3 months after stopping study
             chemotherapy.
Clinical trial NCT03045523 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: glpg2222 150 mg q.d., glpg2222 300 mg q.d., placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female subject ≥ 18 years of age, on the day of signing the Informed Consent
             Form (ICF).

          2. A confirmed clinical diagnosis of CF.

          3. One F508del mutation on one allele in the CFTR gene, a gating (class III) mutation
             (one of the following: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or
             S549R) on the 2nd allele in the CFTR gene (documented in the subject's medical record
             or CF registry).

          4. Weight ≥ 40 kg.

          5. Stable concomitant treatment for at least 4 weeks (28 days) prior to baseline
             (including physician prescribed ivacaftor (Kalydeco®) 150 mg b.i.d.).

          6. Forced expiratory volume in 1 second (FEV1) ≥ 40% of predicted normal for age, gender
             and height at screening (pre- or postbronchodilator).

        Exclusion Criteria:

          1. History of clinically meaningful unstable or uncontrolled chronic disease that makes
             the subject unsuitable for inclusion in the study in the opinion of the investigator.

          2. Unstable pulmonary status or respiratory tract infection (including rhinosinusitis)
             requiring a change in therapy within 4 weeks of baseline.

          3. Need for supplemental oxygen during the day, and >2 liters per minute (LPM) while
             sleeping.

          4. History of hepatic cirrhosis with portal hypertension (e.g., signs/symptoms of
             splenomegaly, esophageal varices, etc).

          5. Abnormal liver function test at screening; defined as aspartate aminotransferase (AST)
             and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or total
             bilirubin (>1.5 times ULN (CTCAE Grade 2) and/or gamma-glutamyl transferase (GGT) ≥ 3x
             the upper limit of normal (ULN), and/or total bilirubin (>1.5 times ULN (CTCAE Grade
             2).

          6. Estimated creatinine clearance < 60mL/min using the Cockroft-Gault formula at
             screening.
Clinical trial NCT03046758 (phase 2, status: completed)
Conditions: appendicitis
ICD codes: K36, K37, K35.80, K35.20, K35.21, K35.890, K35.891
Drugs: a combination of fosfomycin, metronidazole and gm-csf i.p.
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Men ≥18 years old

          -  Suspicion of acute appendicitis and planned for diagnostic laparoscopy and eventual
             appendectomy

          -  Written informed consent after written and verbal information

        Exclusion Criteria:

          -  Cannot understand, read or speak Danish

          -  Previous allergic reaction to fosfomycin, metronidazole, or GM-CSF

          -  Perforated appendicitis (diagnosed either during surgery or at a preoperative computer
             tomography (CT) scan)

          -  Diagnostic laparoscopy revealing normal appendix not requiring an appendectomy

          -  Other intra-abdominal pathology requiring surgical intervention (diagnosed either
             during surgery or at a preoperative CT-scan)

          -  Known renal or hepatic disease or biochemical evidence at the time of admission

          -  Known autoimmune disease or other chronic inflammation

          -  Known hematologic disease or cancer

          -  Previous abdominal surgery (either laparoscopic or open surgery)

          -  Daily use or use of medication one week prior to or during the trial period apart from
             painkillers such as paracetamol, ibuprofen, tramadol, and morphine as well as drugs
             needed for anaesthesia, thrombosis prophylaxis, and nausea. Limitations for
             antibiotics are defined below

          -  Use of other antimicrobial agents than the trial treatment one month before until 24
             hours after the trial treatment

          -  Participant in another drug trial one month prior to the date of the surgery

          -  Body mass index ≥35 kg/m2

          -  Weekly intake of alcohol >14 units, where one unit corresponds to 12 g alcohol
Clinical trial NCT03051100 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: bempedoic acid 180mg, ezetimibe 10mg, atorvastatin 20mg
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Fasting LDL-cholesterol between 130 - 189 mg/dL at screening following washout of all
             LDL-C-lowering drugs and nutritional supplements

          -  Men and nonpregnant, nonlactating women

          -  Sufficiently stable and suitable to undergo washout of all LDL-C-lowering drugs and
             nutritional supplements for 12 weeks

        Exclusion Criteria:

          -  Fasting blood triglycerides greater than or equal to 400 mg/dL

          -  Body Mass Index (BMI) greater than 50 kg/m2

          -  History of clinically significant cardiovascular disease

          -  History of type 1 or type 2 diabetes
Clinical trial NCT03054337 (phase 2, status: completed)
Conditions: anemia, non-dialysis dependent chronic kidney disease
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: vadadustat, placebo
SMILES: OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female Japanese subjects ≥20 years of age

          -  Diagnosis of CKD based on an estimated glomerular filtration rate ≤60 mL/min/1.73 m2

          -  Hb ≤10.5 g/dL

          -  Not currently being treated with dialysis and not expected to start dialysis within 3
             months of screening

        Exclusion Criteria:

          -  Anemia due to a cause other than CKD or presence of active bleeding or recent blood
             loss

          -  Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic
             malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia

          -  Red blood cell transfusion within 4 weeks prior to or during screening

          -  Intravenous iron within 4 weeks prior to or during screening

          -  Any use of erythropoiesis-stimulating agents within 6 weeks prior to or during
             screening
Clinical trial NCT03054350 (phase 2, status: completed)
Conditions: anemia, dialysis dependent chronic kidney disease
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: vadadustat, placebo
SMILES: OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female Japanese subjects ≥20 years of age

          -  Receiving chronic maintenance hemodialysis for end-stage kidney disease

          -  Hb <10.0 g/dL

        Exclusion Criteria:

          -  Anemia due to a cause other than CKD or presence of active bleeding or recent blood
             loss

          -  Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic
             malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia

          -  Red blood cell transfusion within 4 weeks prior to or during screening

          -  Anticipated to recover adequate kidney function to no longer require hemodialysis
             during study participation
Clinical trial NCT03059446 (phase 2, status: terminated)
Conditions: nonalcoholic steatohepatitis, liver cirrhosis, non-alcoholic fatty liver disease
ICD codes: K75.81, K74.60, K74.69, P78.81, K71.7, K70.30, K70.31, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: cenicriviroc
SMILES: CCCCOCCOC1=CC=C(C=C1)C1=CC=C2N(CC(C)C)CCC\C(=C/C2=C1)C(=O)NC1=CC=C(C=C1)[S@@+]([O-])CC1=CN=CN1CCC
Reason stopped: 
    this study was terminated early due to lack of efficacy based on the results of part i of the
    aurora study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Successful completion of both Treatment Period 1 and Treatment Period 2, of the
             CENTAUR Study (652-2-203), including a Year 2 liver biopsy.

          -  Completed the AURORA study (3152-301-002) as a result of reaching an adjudicated
             liver-related clinical outcome in Part 1 or Part 2 of the study of:

          -  Histopathological progression to cirrhoses

          -  Model for end-stage liver disease (MELD) score ≥ 15

          -  Ascites (requiring intervention, ie, large volume paracentesis ≥ 1L or initiation of a
             diuretic)

          -  Hospitalization (as defined by a stay of ≥ 24 hours) for onset of variceal bleed,
             hepatic encephalophathy (defined by a West Haven Stage of ≥ 2), spontaneous bacterial
             peritonitis (confirmed by diagnostic paracentesis with positive ascitic fluid
             bacterial culture)

        Exclusion Criteria:

          -  Prior or planned liver transplantation

          -  Other know causes of chronic liver disease such as: Alcoholic liver disease, Primary
             biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hepatitis, Wilson's
             disease, hemochromatosis, or iron overload, or Alpha-1-antitrypsis (A1AT) deficiency.